Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer
Induction Chemotherapy Followed by Chemoradiation With Cetuximab and Cisplatin for Inoperable Squamous Cell Carcinoma of the Head and Neck
調査の概要
詳細な説明
The treatment results with radiotherapy in inoperable squamous cell carcinoma of the head and neck are poor.
In this proposed single-institution non-randomized, one-arm, open label phase II study, the authors will test the efficacy and toxicity of docetaxel/cisplatin/5-fluorouracil induction chemotherapy (4 cycles) followed by concomitant chemoradiation with cetuximab and weekly cisplatin in patients with inoperable squamous cell carcinoma of the head and neck.
Chemotherapy doses will be as follows: docetaxel 75 mg/m2 I.V. day 1, cisplatin 75 mg/m2 I.V. day 1, 5-fluorouracil 750 mg/m2 I.V. continuous infusion days 1-5 repeated every 21 days for 4 cycles followed by cetuximab 400 mg/m2 I.V. week 13, cetuximab 250 mg/m2 I.V. weeks 14-20, cisplatin 30 mg/m2 I.V. weeks 14-20. Three-dimensional conformal radiotherapy planning and delivery (35x2 Gy/day over 7 weeks {weeks 14 - 20}) will be used.
The planned number of patients to be included is 30 and anticipated enrolment period is 12 months.
The primary objective of the study is to determine locoregional control at 2 years post-therapy, whereas secondary objectives are to determine feasibility (toxicity profile) of the proposed regimen, to determine complete response rate after induction ChT as well as 14-16 weeks after the therapy, completion of ChRT to determine disease free survival at 2 years, overall survival at 2 years and late toxicity including thyroid function.
Given the preliminary nature of the study, no stopping rule is prospectively planned outside of observed toxicity, which will be assessed and graded according to Common Terminology Criteria for Adverse Events version 3.0.
研究の種類
入学 (予想される)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
-
Ljubljana、スロベニア、SI-1000
- Institute of Oncology Ljubljana
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Squamous cell carcinoma, histologically proven
- Tumour site: oral cavity, oropharynx, hypopharynx or larynx.
- Locally and/or regionally inoperable tumors (UICC TNM stages IVa or IVb) - - without distant metastases (M0-stage)
- Male or female ≥18 years of age
- Expected survival >6 months
- Presence of at least one bidimensionally measurable index lesion
- Effective contraception for both male and female subjects if risk of conception exists
- WHO performance status 0-2
- Laboratory parameters:
hemoglobin ≥100 g/L leukocyte count > 3.5x109/L, absolute neutrophil count ≥ 1.5x109/L platelet count > 100x109/L total bilirubin < 1.25x upper normal limit transaminases (ALT, AST) < 5x upper normal limit creatinine clearance ≥ 55 mls/minute
- Signed written informed consent
Exclusion Criteria:
- Metastatic disease
- Squamous cell carcinoma of the nasopharynx and nasal cavity and paranasal sinuses
- ChT or XRT ineligibility:
Unstable cardiac disease or any other medical condition likely to compromise the safe delivery of ChT or XRT; Clinically evident hearing impairment; Pre-existing motor or sensory neurotoxicity grade ≥ 2 according to the CTCAE v3.0;
- Any kind of previous therapy for SCCHN (excluding diagnostic biopsy)
- Previous administration of EGFR pathway-targeting therapy
- Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy which is not part of the study protocol
- Participation in another clinical trial within 30 days prior to study entry
- Pregnancy or breast feeding
- History of severe acute pulmonary disease
- Any investigational agent within past 30 days
- Other previous malignancy within 5 years, with exception of a history of a previously adequately treated basal cell carcinoma of the skin or pre- invasive carcinoma of the cervix
- Known drug abuse / severe alcohol abuse
- Legal incapacity or limited legal capacity
- Medical or psychological condition which in the opinion of the investigator would not permit the subject to complete the study or sign meaningful informed consent
- Active, uncontrolled infection
- Other medical condition or other therapy that in the opinion of the investigator precludes the safe administration of the planned ChT and XRT
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
locoregional control
時間枠:at 2 years post-therapy
|
at 2 years post-therapy
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
feasibility (toxicity profile) of the proposed regimen
時間枠:during therapy
|
during therapy
|
complete response rate
時間枠:after induction ChT and 14-16 weeks after the therapy
|
after induction ChT and 14-16 weeks after the therapy
|
disease free survival
時間枠:at 2 years post-therapy
|
at 2 years post-therapy
|
overall survival
時間枠:at 2 years post-therapy
|
at 2 years post-therapy
|
late toxicity including thyroid function
時間枠:up to 2 years post-therapy
|
up to 2 years post-therapy
|
協力者と研究者
捜査官
- 主任研究者:Primož Strojan, MD、Dept. of Radiation Oncology, Institute of Oncology Ljubljana, Slovenia
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
docetaxel, cisplatin, 5-fluorouracilの臨床試験
-
Encube Ethicals Pvt. Ltd.CBCC Global Research完了